NCT03883698View on ClinicalTrials.gov

Safety of Sofosbuvir in People With Advanced Kidney Failure

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 15, 2019

Primary Completion Date

August 1, 2020

Study Completion Date

August 1, 2020

Conditions
Kidney Failure, ChronicHepatitis C
Interventions
DRUG

Sofosbuvir

Sofosbuvir is the backbone of the most of the currently used anti-HCV treatment regimens

DRUG

Daclatasvir 60 mg

Daclatasvir, in combination with sofosbuvir, is approved for the treatment of hepatitis C virus infection in absence of liver cirrhosis

Trial Locations (1)

226014

Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow

All Listed Sponsors
lead

Sanjay Gandhi Postgraduate Institute of Medical Sciences

OTHER_GOV

NCT03883698 - Safety of Sofosbuvir in People With Advanced Kidney Failure | Biotech Hunter | Biotech Hunter